热门资讯> 正文
箭头因与萨雷普塔合作而陷入困境
2025-07-21 23:58
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down ~22% since market close on July 18 and the reason could be that the company has several early-stage candidates in partnership with recently belaguered Sarepta Therapeutics (NASDAQ:SRPT).
- Arrowhead closed July 19 down ~11% and is down another ~11% in late Monday morning trading.
- Sarepta and Arrowhead have four phase 1 candidates they are working on together: ARO-DUX4 for facioscapulohumeral muscular dystrophy type 1; ARO-DM1 for myotonic dystrophy type 1; ARO-ATXN2 for spinocerebellar ataxia 2; and ARO-ATXN2 for spinocerebellar ataxia 2
- Arrowhead also has two candidates in phase 3, but for cardiometabolic indications.
- Sarepta closed July 19 down ~36% after the U.S. FDA asked the company to voluntarily halt shipments of its Duchenne muscular dystrophy gene therapy Elevidys due to three patients deaths linked to the treatment. Sarepta has declined to do so.
- Earlier Monday, Sarepta disclosed that the FDA had issued clinical holds on trials for several candidates for limb girdle muscular dystrophy.
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade)
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
- SA analyst downgrades: PLTR, PSTG, NTLA, ARWR
- Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum
- Seeking Alpha’s Quant Rating on Arrowhead Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
